MESANTOIN
LOE ApproachingNDAORALTABLET
Approved
Oct 1946
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MESANTOIN (mephenytoin) is an oral small-molecule anticonvulsant approved in 1946 for seizure management. It functions as a hydantoin-class antiepileptic drug that stabilizes neuronal membranes. The drug is indicated for patients with generalized tonic-clonic and complex partial seizures.
LOE Approaching
As LOE approaches, brand team focus shifts to lifecycle extension, generic transition planning, and potential discontinuation strategies; team size likely modest given legacy product status.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MESANTOIN offers limited career upside given zero linked job openings and approaching loss-of-exclusivity; roles are primarily defensive and focused on retaining market share among legacy users. This assignment is better suited to early-career professionals seeking experience in specialty/mature markets or those transitioning toward market access functions.
Managed Care Specialist
Worked on MESANTOIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.